Fatty Liver

Fatty liver, also known as fatty liver disease (FLD), is a reversible condition where large vacuoles of triglyceride fat accumulate in liver cells via the process of steatosis (i.e. abnormal retention of lipids within a cell).

What is Fatty Liver?

Fatty liver is a very common disorder and up to 20 percent of adults and approximately 5 percent of children are affected.

Fatty Liver Pathology

Fatty Liver Diagnosis

Acute Fatty Liver of Pregnancy Treatment

How gut microbiota impacts childhood obesity

Gut microbiota plays a critical role in childhood obesity by influencing energy metabolism, inflammation, and appetite regulation, with emerging therapeutic strategies like probiotics, dietary interventions, and fecal microbiota transplantation showing promise.

21 Jan 2025

Junk food turns public villain as power shifts in Washington

The new Trump administration could be coming for your snacks. For years, the federal government has steered clear of regulating junk food, fast food, and ultra-processed food.

17 Jan 2025

Air pollution amplifies dementia risk in cardiometabolic disease patients - healthy habits can help

CMD patients face a 2x higher risk of dementia and MCI, but healthier lifestyles can counter air pollution's impact and reduce these risks.

16 Jan 2025

Proteomic mapping identifies biomarkers driving healthy aging and preventing chronic diseases

Scientists mapped the serum proteome longitudinally to uncover biomarkers linked to healthy aging and cardiometabolic diseases, revealing potential therapeutic targets.

14 Jan 2025

New research sheds light on changing liver cancer trends

Liver cancer is a leading cause of cancer-related deaths worldwide, with distinct geographic patterns in its incidence.

13 Jan 2025

Gut microbes and the body work together to regulate fat metabolism

Beneficial gut microbes and the body work together to fine-tune fat metabolism and cholesterol levels, according to a new preclinical study by investigators from Weill Cornell Medicine and the Boyce Thompson Institute at Cornell University's Ithaca campus.

9 Jan 2025

Nuclear lipid droplets could play a key role in aging and disease

A new research perspective was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 16, Issue 22 on December 9, 2024, entitled "Nuclear lipid droplets: a novel regulator of nuclear homeostasis and aging."

7 Jan 2025

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Under Rhiannon White's leadership, Clue is transforming menstrual health tracking into a powerful tool for research and improved reproductive health outcomes.

3 Jan 2025

Researchers develop tool to measure biological age in individual cell types

A new priority research paper, featured as the cover of Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 16, Issue 22, was published on December 29, 2024. The paper is titled "Cell-type specific epigenetic clocks to quantify biological age at cell-type resolution."

2 Jan 2025

Study reveals how fatty liver disease leads to liver cancer

Scientists at University of California San Diego School of Medicine have shed new light on the development of liver cancer, the sixth most frequently diagnosed cancer and fourth leading cause of cancer deaths worldwide.

2 Jan 2025

The role of phytochemicals in combating metabolic diseases

This editorial reviews the impact of phytochemicals on metabolic diseases, emphasizing their potential in reducing inflammation and improving health outcomes.

19 Dec 2024

New drug approach shows promise in treating metabolic liver diseases

A MedUni Vienna study has identified a new approach to the drug treatment of metabolic liver diseases. In an experimental study, pharmacological inhibition of an enzyme that plays a central role in fat metabolism promoted liver health reduced liver fat, inflammation and fibrotic remodeling (connective tissue scarring).

18 Dec 2024

Revolutionizing MASLD treatment with GLP-1 receptor agonists

Researchers explore the therapeutic potential and clinical insights of GP1-RAs in the management of metabolic dysfunction-associated steatotic liver disease.

16 Dec 2024

New study identifies potential target for treating diabetic cardiomyopathy

Some patients with diabetes develop a serious condition known as diabetic cardiomyopathy, which is slow and cannot be directly attributed to hypertension or other cardiovascular disorders.

12 Dec 2024

Two distinct types of fatty liver disease identified

Researchers at Karolinska Institutet and the University of Gothenburg have identified two types of metabolic-associated fatty liver disease - a liver-specific type and a systemic type that affects other organs and tissues.

10 Dec 2024

Tea, apples, and chocolate proven to support liver health

A flavonoid-rich diet, including apples, tea, and dark chocolate, significantly lowers the risk of non-alcoholic fatty liver disease (NAFLD) and improves liver health biomarkers. These findings highlight the potential of dietary flavonoids in combating liver fat accumulation and inflammation.

9 Dec 2024

Two new subtypes of MASH revealed with different risks and outcomes

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly referred to as nonalcoholic fatty liver disease (NAFLD), impacts roughly 30% of the global adult population.

9 Dec 2024

New compound HPH-15 offers promising alternative to diabetes medications

Kumamoto University scientists have unveiled a novel compound, HPH-15, with dual effects of reducing blood glucose levels and combating fat accumulation, marking a significant leap in diabetes treatment innovation.

6 Dec 2024

AI tool detects heart disease in CT scans originally meant for other purposes

With the help of an artificial intelligence (AI) tool, computed tomography (CT) scans taken to look for tumors or bleeding or infections, also revealed calcium buildup in arteries, a sign of worsening cardiovascular disease.

4 Dec 2024

Disrupted sleep-wake rhythms linked to liver disease progression

The prevalence of MASLD (metabolic dysfunction-associated steatotic liver disease) is exploding in most regions of the world, boosted by increased obesity and sedentary lifestyles. MASLD (formerly known as non-alcoholic fatty liver disease) is already the most common liver disorder: it affects 30% of adults and between 7% and 14% of children and adolescents, and this prevalence is predicted to rise to more than 55% of adults by 2040.

4 Dec 2024